Search

Research Grants process explained

After creating the account, you can choose which project to select in the upper left corner. Be sure to select the one for applicants.

Read more

EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia

Dates: April 12-14, 2018
Location: Barcelona, Spain
Chair: N Gökbuget
Co-chairs: R Bassan, H Dombret, A Fielding, R Foà, D Hoelzer, JM Ribera

EHA and the EHA Scientific Working Group on Acute Lymphoblastic Leukemia are organizing their second EHA-SWG Scientific Meeting on Acute Lymphoblastic Leukemia.…

Read more

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

Fellowships & Grants Committee

Current committee members
Dominique Bonnet, United Kingdom (Chair (EHA Board))
David Kent, United Kingdom (Vice-Chair (non-Board))
Regular members
Renée Beekman, Spain
Olivier Bernard, France
Niccolò Bolli, Italy
Tom Cupedo, The Netherlands
Michaela Fontenay, France
Julia Hauer, Germany
Antonis Kattamis, Greece
Elisa Laurenti, United Kingdom
Dimitrios Mougiakakos, Germany
César Nombela-Arrieta, Switzerland
Rebekka Schneider-Kramann, The Netherlands
Jürg…

Read more

Challenges and opportunities in the diagnostics and management of onco-hematological patients under the microscope during tutorial in Russia

Onco-hematology was the focus of the two-day EHA Hematology Tutorial in Moscow, Russia, the third joint tutorial organized by EHA, the National Hematological Society (NHS) and the Russian-Oncohematology Society (ROHS).

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more